



Sally Arai

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

CLINICAL OFFICE (PRIMARY)

- **Blood and Marrow Transplant Program**

300 Pasteur Dr Rm H0101

MC 5623

Stanford, CA 94305

Tel (650) 723-0822 Fax (650) 725-8950

Bio

BIO

Dr. Arai has formal training in clinical research with a Masters in Epidemiology from Stanford University. She has a clinical practice seeing all diseases in hematopoietic cell transplantation, with a clinical research focus on the prevention and treatment of post-transplant complications.

CLINICAL FOCUS

- Cancer > Blood and Marrow Transplant
- Cancer > Hematology
- Blood and Marrow Transplantation
- Hematology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Blood & Marrow Transplantation
- Member, Stanford Cancer Institute

HONORS AND AWARDS

- "A phase I/II study of post-transplant autologous CIK cells for high-risk hematologic malignancies", Cancer Treatment Research Foundation (2005-2009)
- K23-"Reduce GVHD and Relapse using Ex-Vivo Expanded Allogeneic Cell Therapy", NIH (2003-2008)

PROFESSIONAL EDUCATION

- Medical Education: Dartmouth Geisel School of Medicine (1991) NH
- Board Certification: Hematology, American Board of Internal Medicine (2019)
- Fellowship: Johns Hopkins Hospital (1999) MD
- Residency: Strong Memorial Hospital (1995) NY
- Fellowship: Mount Sinai Medical Center (1998) NY

- Internship: Strong Memorial Hospital (1993) NY
- MS, Stanford University , Epidemiology (2006)
- MD, Dartmouth Medical School

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Research interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.

CLINICAL TRIALS

- Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Recruiting
- Expanded Access Protocol (EAP) for Nonconforming (NC) Afami-cel, Recruiting
- A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease, Not Recruiting
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial), Not Recruiting
- A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant, Not Recruiting
- A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD), Not Recruiting
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease, Not Recruiting
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM), Not Recruiting
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802), Not Recruiting
- Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies, Not Recruiting
- An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD), Not Recruiting
- Autologous Stem Cell Rescue for Primary Amyloidosis, Not Recruiting
- CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma, Not Recruiting
- Chronic GVHD Response Measures Validation, Not Recruiting
- Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702), Not Recruiting
- Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study, Not Recruiting
- Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoietic Stem Cell Transplant Patients, Not Recruiting
- Detection of Graft Versus Host Disease With [18F]F-AraG, Not Recruiting
- Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant, Not Recruiting
- Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy, Not Recruiting
- Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213, Not Recruiting
- Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301), Not Recruiting
- Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease, Not Recruiting
- High Dose Chemotherapy Followed By PBSC Rescue for HD, Not Recruiting
- High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma, Not Recruiting

- High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma, Not Recruiting
- HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide, Not Recruiting
- HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis, Not Recruiting
- Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease, Not Recruiting
- Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation, Not Recruiting
- MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies, Not Recruiting
- Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203), Not Recruiting
- Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation, Not Recruiting
- Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502), Not Recruiting
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD, Not Recruiting
- Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies, Not Recruiting
- Proof-of-concept Trial of Apraglutide in GVHD, Not Recruiting
- Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma, Not Recruiting
- Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease, Not Recruiting
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD, Not Recruiting
- Transplantation for Patients With Chronic Lymphocytic Leukemia, Not Recruiting
- Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705), Not Recruiting
- Bone Marrow Grafting for Leukemia and Lymphoma, Not Specified

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

Publications

PUBLICATIONS

- **The Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024.** *Transplantation and cellular therapy*
Uzun, D., Paul, J. M., Jensen, A., Tamaresis, J., Domingo, W., Arai, S., Ventura, F. A., Rocha, J., Bennett, L., Jones, A., Bharadwaj, S., Johnston, L., Lowsky, et al
2025
- **Bronchiectasis in bronchiolitis obliterans syndrome after hematopoietic cell transplantation.** *Transplantation and cellular therapy*
Epstein, D. J., Rodriguez-Ormaza, N., Sharifi, H., Lai, Y. K., Guo, H. H., Borges, C. H., Omar, S. H., Sahota, A., Dhillon, E. S., Musa, Z. M., Moss, C. T., Chatterjee, P., Hofmann, et al
2025
- **Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Al Malki, M. M., Bo-Subait, S., Logan, B., Olson, J., Kou, J., Smith, S., Leckrone, E., Wu, J., Stefanski, H. E., Auletta, J. J., Spellman, S. R., Malmberg, C., Askar, et al
2025: JCO2500856
- **The Impact of Melphalan Conditioning and CD34+ Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis.** *American journal of hematology*

- Muchtar, E., Sanchorawala, V., Hassan, H., Hegenbart, U., Schönland, S., Lee, H. C., Qazilbash, M., Kin, A., Zonder, J., Jacob, E., Buadi, F., Dispenzieri, A., Dingli, et al
2025
- **KIDNEY FUNCTION IN ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS TREATED WITH ORCA-T GVHD PROPHYLAXIS COMPARED TO POST TRANSPLANT CYCLOPHOSPHAMIDE OR METHOTREXATE**
Ziolkowski, S., Villar-Prados, A., Parvathinathan, G., Okabuonye, N., Johnston, L., Arai, S., Stedman, M., Anand, S., Meyer, E.
W B SAUNDERS CO-ELSEVIER INC.2025
 - **A model for predicting day-100 stem cell transplant-related mortality in AL amyloidosis.** *Bone marrow transplantation*
Muchtar, E., Dispenzieri, A., Sanchorawala, V., Hassan, H., Mwangi, R., Maurer, M., Buadi, F., Lee, H. C., Qazilbash, M., Kin, A., Zonder, J., Arai, S., Chin, et al
2025
 - **Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.** *Nature communications*
Hosoya, H., Carleton, M., Tanaka, K., Sworder, B., Syal, S., Sahaf, B., Maltos, A. M., Silva, O., Stehr, H., Hovanky, V., Duran, G., Zhang, T., Liedtke, et al
2025; 16 (1): 1824
 - **Efficacy of Hedgehog Pathway Inhibitors as Adjuvant in Treating Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease.** *Journal of the American Academy of Dermatology*
Mendez-Hernandez, A., Gupta, R., Arai, S., Lowsky, R., Kwong, B., Weng, W. K.
2025
 - **Donor Regulatory T-Cell Therapy to Prevent Graft-Versus-Host Disease.** *Blood*
Meyer, E., Pavlova, A., Villar-Prados, A., Bader, C. S., Xie, B., Muffly, L., Kim, P., Sutherland, K. C., Bharadwaj, S., Dahiya, S., Frank, M. J., Arai, S., Johnston, et al
2025
 - **Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.** *Bone marrow transplantation*
Chin, M. M., Tamaresis, J. S., Johnston, L. J., Lowsky, R., Meyer, E., Muffly, L., Shiraz, P., Frank, M. J., Rezvani, A. R., Bharadwaj, S., Weng, W. K., Shizuru, J. A., Arai, et al
2024
 - **Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms**
Hamilton, M., Phillips, N., Lee, D., Ehlinger, Z., Kramer, A., Srinagesh, H., Good, Z., Kang, X., Olsen, M., Liu, C., Tian, F., Sworder, B. J., Hosoya, et al
ELSEVIER.2024: 96-97
 - **Spatial Characterization of Molecular Pathways Suggests the Dysregulation of LGR5 Expressing Fibroblasts in Patients with sclerodermatous Chronic Graft-Vs-Host Disease**
Afrin, M., Nasr, S., De Souza, C., Howitt, B., Mueller, A., Arai, S., Shizuru, J., Wernig, G.
ELSEVIER.2024
 - **A Standard Operating Protocol for Pre-Transplant Low Dose Splenic Radiotherapy for Patients with Myelofibrosis**
Baniel, C., Park, N., Klebaner, D., Shomali, W., Gotlib, J., Arai, S., Hiniker, S., Hoppe, R. T., Johnston, L., Binkley, M. S.
ELSEVIER.2024: 2116-2117
 - **CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma**
Kramer, A., Srinagesh, H., Su, Y., Hamilton, M. P., Levine, K., Migliore, E., Denoble, K., Brown, A. K., Cunanan, K., Agarwal, N., Lohman, C., Mavroukakis, S., Bharadwaj, et al
ELSEVIER.2024: 2064-2066
 - **Trial in Progress: Cureaa- a Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia, Blood and Marrow Transplant Clinical Trials Network (BMT CTN) #2207**
Sharma, A., Mangaonkar, A. A., Kassim, A. A., Fritz, A. R., Bellach, A., Saldana, B., Ball, B. J., Malmberg, C., Babushok, D., Henderson, L., Pandey, M., Martens, M. J., Difronzo, et al
ELSEVIER.2024: 21341-21342

- **Safe and Effective Combination of Donor-Derived, Allogeneic CD19/CD22-CAR T Cells with Myeloablative Graft-Engineered Allo-HCT for High-Risk B-ALL**
Muffly, L., Ananth, S., Danley, L., Wagner, C., Kordek, D., Denoble, K., Fraser, A., Egeler, E., Molina, A., Ehlinger, Z., Desai, M., Daghigh, H., Tunuguntla, et al
ELSEVIER.2024: 680
- **Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Octogenarian Patients (Aged > 80) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)**
Lee, D., Bharadwaj, S., Rana, M. S., Jensen, A., Wang, W., Ghalehsari, N., Sahaf, B., Mallampet, J., Elkordy, S., Latchford, T., Arai, S., Johnston, L., Hosoya, et al
ELSEVIER.2024: 386-387
- **Model for Predicting Day-100 Stem Cell Transplant-Related Mortality in AL Amyloidosis**
Mughtar, E., Dispenzieri, A., Sanchorawala, V., Hassan, H., Mwangi, R., Maurer, M. J., Buadi, F., Lee, H. C., Qazilbash, M. H., Kin, A., Zonder, J. A., Arai, S., Chin, et al
ELSEVIER.2024: 4681-4682
- **Cytokines associated with organ manifestations in chronic graft-versus-host disease**
Lee, S. J., Ma, N., Randolph, T., Kitko, C. L., Cutler, C. S., El Jurdi, N., Chen, G., Hamilton, B. K., Pidala, J. A., Carpenter, P. A., Arai, S., Onstad, L., Paczesny, et al
ELSEVIER.2024: 4902-4903
- **Outcomes of Autologous Stem Cell Transplant in Older Adults with Relapsed/Refractory Classic Hodgkin Lymphoma**
Desai, S. H., Spinner, M. A., Sykorova, A., Bachanova, V., Evens, A. M., Goyal, G., Kahl, B. S., Dorritie, K., Azzi, J., Kenkre, V. P., Chang, C., Michalka, J., Ansell, et al
ELSEVIER.2024: 570-572
- **Anti-BCMA CAR T-Cell Expansion and Its Association with Response and Toxicity in Multiple Myeloma**
Hosoya, H., Jensen, A., Hovanky, V., Homsy, S., Cancilla, J. E., Patil, S., Kennedy, V. E., Bharadwaj, S., Smith, M., Shiraz, P., Frank, M. J., Dahiya, S., Arai, et al
ELSEVIER.2024: 2006-2007
- **CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up**
Kramer, A., Baird, J. H., Srinagesh, H., Egeler, E., Levine, K., Brown, A. K., Mavroukakis, S., Cunanan, K., Su, Y., Agarwal, N., Hamilton, M. P., Bharadwaj, S., Arai, et al
ELSEVIER.2024: 70-71
- **Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma. *Blood cancer journal***
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S. K., Holmes, T. H., Tamaresis, J., Le, A., Muffly, L. S., Maysel-Auslender, S., Johnston, L., Arai, S., Lowsky, R., Meyer, et al
2024; 14 (1): 173
- **Long-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study *ECLINICALMEDICINE***
Eapen, M., Antin, J. H., Tolar, J., Arai, S., Horwitz, M. E., Kou, J., Leifer, E., McCarty, J. M., Nakamura, R., Pulsipher, M. A., Rowley, S. D., Horowitz, M. M., Deeg, et al
2024; 76
- **PHASE 1 TRIAL RESULTS FOR PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES TREATED WITH ORCA-T CELL THERAPY WITH REDUCED INTENSITY CONDITIONING AND SINGLE AGENT TACROLIMUS**
Villar-Prados, A., Sutherland, K., Negrin, R., Arai, S., Frank, M., Johnston, L., Lowsky, R., Miklos, D., Muffly, L., Dahiya, S., Rezvani, A., Sidana, S., Shiraz, et al
SPRINGERNATURE.2024: 287-288
- **Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines from the American Society for Transplantation and Cellular Therapy. *Transplantation and cellular therapy***
Iftikhar, R., DeFilipp, Z., DeZern, A. E., Pulsipher, M. A., Bejanyan, N., Burroughs, L. M., Kharfan-Dabaja, M. A., Arai, S., Kassim, A., Nakamura, R., Saldaña, B. J., Aljurf, M., Hamadani, et al
2024

- **Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.** *The New England journal of medicine*
Wolff, D., Cutler, C., Lee, S. J., Pusic, I., Bittencourt, H., White, J., Hamadani, M., Arai, S., Salhotra, A., Perez-Simon, J. A., Alousi, A., Choe, H., Kwon, et al
2024; 391 (11): 1002-1014
- **Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial.** *medRxiv : the preprint server for health sciences*
Dehn, J. G., Logan, B., Shaw, B. E., Devine, S., Ciurea, S. O., Horowitz, M., He, N., Pusic, I., Srour, S. A., Arai, S., Juckett, M., Uberti, J., Hill, et al
2024
- **CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.** *Lancet (London, England)*
Frank, M. J., Baird, J. H., Kramer, A. M., Srinagesh, H. K., Patel, S., Brown, A. K., Oak, J. S., Younes, S. F., Natkunam, Y., Hamilton, M. P., Su, Y. J., Agarwal, N., Chinnasamy, et al
2024
- **A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia.** *Blood*
Srinagesh, H. K., Jackson, C., Shiraz, P., Jeyakumar, N., Hamilton, M. P., Egeler, E., Mavroukakis, S., Kuo, A., Cancilla, J., Sahaf, B., Agarwal, N., Kanegai, A. M., Kramer, et al
2024
- **Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.** *Journal for immunotherapy of cancer*
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H., Jensen, A., Lee, D., Mallampet, J., Elkordy, S., Syal, S., Patil, S., Latchford, T., Sahaf, et al
2024; 12 (7)
- **Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation.** *Blood advances*
Pidala, J. A., Onstad, L., Baumrin, E., Carpenter, P. A., Cutler, C. S., Arai, S., Kitko, C. L., Chen, G. L., Lee, S. J.
2024
- **A predictive model for day-100 transplant-related mortality in AL amyloidosis**
Mughtar, E., Dispenzieri, A., Sanchorawala, V., Hassan, H., Mwangi, R., Maurer, M., Lee, H., Qazilbash, M., Kin, A., Zonder, J., Buadi, F. K., Arai, S., Chin, et al
TAYLOR & FRANCIS LTD.2024: S186-S187
- **Management of post-autologous transplant relapse in patients with T-cell lymphomas.** *American journal of hematology*
Veilleux, O., Socola, F., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Shizuru, J., Meyer, E., Muffly, L., Rezvani, A. R., Shiraz, P., Sidana, S., Dahiya, et al
2024
- **CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.** *Blood advances*
Hamilton, M. P., Craig, E., Gentile Sanchez, C., Mina, A., Tamaresis, J., Kirmani, N., Ehlinger, Z., Syal, S., Good, Z., Sworder, B., Schroers-Martin, J., Lu, Y., Muffly, et al
2024
- **CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results.** *Leukemia*
Schultz, L. M., Jeyakumar, N., Kramer, A. M., Sahaf, B., Srinagesh, H., Shiraz, P., Agarwal, N., Hamilton, M., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Arai, et al
2024
- **Long-Term Clinical Outcomes and B Cell Immune Reconstitution following Allo-HCT with Prophylactic, Post-Transplant Rituximab.** *Transplantation and cellular therapy*
Kennedy, V. E., Sahaf, B., Wu, F., Ehlinger, Z. J., Arai, S., Miklos, D. B.
2024
- **Single Center Randomized Trial of T-reg graft alone versus T-reg graft Plus Tacrolimus for the Prevention of Acute GVHD.** *Blood advances*
Bader, C. S., Pavlova, A., Lowsky, R., Muffly, L., Shiraz, P., Arai, S., Johnston, L. J., Rezvani, A. R., Weng, W. K., Miklos, D. B., Frank, M. J., Tamaresis, J. S., Agrawal, et al
2023

- **CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias**
Hamilton, M. P., Sworder, B. J., Alig, S. K., Good, Z., Boegeholz, J., Schroers-Martin, J., Tamaresis, J., Esfahani, M., Lu, Y., Olsen, M., Liu, C., Ehlinger, Z., Desai, et al
AMER SOC HEMATOLOGY.2023
- **The Impact of Melphalan Conditioning Schedule on Post-Transplant Outcomes in AL Amyloidosis: A Multicenter Study with 1718 Patients**
Muchtar, E., Sancharawala, V., Hassan, H., Hegenbart, U., Schonland, S., Lee, H. C., Qazilbash, M. H., Kin, A., Houde, C. A., Buadi, F., Dispenzieri, A., Jacob, E. K., Arai, et al
AMER SOC HEMATOLOGY.2023
- **Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)**
Wolff, D., Cutler, C., Lee, S. J., Pusic, I., Bittencourt, H., White, J., Hamadani, M., Arai, S., Salhotra, A., Perez-Simon, J. A., Alousi, A., Choe, H., Kwon, et al
AMER SOC HEMATOLOGY.2023
- **Long-Term Outcomes after Unrelated Marrow Transplantation for Aplastic Anemia with Optimized Cyclophosphamide Dose (BMT CTN 0301)**
Eapen, M., Antin, J., Tolar, J., Arai, S., Horwitz, M., Kou, J., Leifere, E., McCarty, J. M., Nakamura, R., Pulsipher, M. A., Horowitz, M. M., Deeg, H.
AMER SOC HEMATOLOGY.2023
- **Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus**
Villar-Prados, A., Meyer, E. H., Sutherland, K., Negrin, R. S., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Miklos, D. B., Muffly, L. S., Dahiya, S., Rezvani, A. R., Sidana, et al
AMER SOC HEMATOLOGY.2023
- **Targeting of CD25+Activated T Cells in Gvhd-Associated Marrow Suppression and Cytopenias**
John, T. D., Valine, L., Barbarito, G., Kwon, H., Arai, S., Martin-Kool, B., Kumari, R., Shizuru, J., Oak, J. S., Parkman, R., Bertaina, A., Weinberg, K. I.
AMER SOC HEMATOLOGY.2023
- **A NOVEL DONOR SEARCH AND SELECTION ALGORITHM FACILITATES A COMPARABLE INCIDENCE OF TRANSPLANT FOR PATIENTS REGARDLESS OF BASELINE SEARCH PROGNOSIS: REPORT FROM BMTCTN 1702 TRIAL**
Dehn, J., Logan, B., He, N., Shaw, B. E., Devine, S., Vogel, J., Erickson, C., Ciurea, S., Lee, S. J., Westervelt, P., Srour, S., Arai, S., Juckett, et al
SPRINGERNATURE.2023: 150-152
- **Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. *Blood cancer journal***
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., Sahaf, B., Bharadwaj, S., Latchford, T., Arai, S., Leahy, S., Mei, M., Budde, et al
2023; 13 (1): 158
- **Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era. *Blood advances***
Desai, S. H., Spinner, M. A., Evens, A. M., Sýkorová, A., Bachanova, V., Goyal, G., Kahl, B. S., Dorritie, K. A., Azzi, J., Kenkre, V. P., Chang, C., Michalka, J., Ansell, et al
2023
- **Patient-reported treatment response in chronic graft-versus-host disease. *Haematologica***
Im, A., Pusic, I., Onstad, L., Kitko, C. L., Hamilton, B. K., Alousi, A. M., Flowers, M. E., Sarantopoulos, S., Carpenter, P., White, J., Arai, S., El Jurdi, N., Chen, et al
2023
- **Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals**
Wadsworth, P., De Souza, C., Cui, L., Yiu, C., Poyser, J., Rieger, K., Brown, R., Arai, S., Shizuru, J., Muller, A., Wernig, G.
ELSEVIER SCIENCE INC.2023: S1252-S1253
- **Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents. *Blood***
Spinner, M. A., Sica, R. A., Tamaresis, J. S., Lu, Y., Chang, C., Lowsky, R., Frank, M. J., Johnston, L. J., Miklos, D. B., Muffly, L., Negrin, R. S., Rezvani, A. R., Shiraz, et al
2023
- **Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma. *American journal of hematology***

- Desai, S. H., Spinner, M. A., David, K., Bachanova, V., Goyal, G., Kahl, B., Dorritie, K., Azzi, J., Kenkre, V. P., Arai, S., Chang, C., Fusco, B., Sumransub, et al
2023
- **Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.** *Seminars in oncology*
Testa, S., Kumar, J., Goodell, A. J., Zehnder, J. L., Alexander, K. M., Sidana, S., Arai, S., Witteles, R. M., Liedtke, M.
2022
 - **Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals**
Cui, L., De Souza, C., Lerbs, T., Poyser, J., Yu, C., Rieger, K., Arai, S., Brown, R., Shizuru, J. A., Mueller, A., Wernig, G.
AMER SOC HEMATOLOGY.2022
 - **Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects**
Hamilton, M. P., Liu-Fei, F. C., Alig, S. K., Tamaresis, J., Esfahani, M., Good, Z., Sworder, B., Schroers-Martin, J., Liu, C., Severinsen, F., Hanson, P. J., Lu, Y., Lowsky, et al
AMER SOC HEMATOLOGY.2022: 7545-7547
 - **The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes**
Philip, S., Srinagesh, H. K., Hamilton, M. P., Gentile, C., Mina, A., Arai, S., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, et al
AMER SOC HEMATOLOGY.2022: 12775-12777
 - **Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref NonHodgkin Lymphoma**
Bharadwaj, S., Hamilton, M. P., Sahaf, B., Tamaresis, J., Patil, S., Hanson, P. J., Latchford, T., Arai, S., Johnston, L. J., Lowsky, R., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2022: 10371-10373
 - **Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease**
Chin, M., Shizuru, J. A., Muffly, L., Shiraz, P., Johnston, L. J., Lowsky, R., Rezvani, A. R., Frank, M. J., Bharadwaj, S., Weng, W., Negrin, R. S., Miklos, D. B., Arai, et al
AMER SOC HEMATOLOGY.2022: 4788-4789
 - **Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era**
Philip, S., Lowsky, R., Johnston, L. J., Arai, S., Meyer, E. H., Negrin, R. S., Rezvani, A. R., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Bharadwaj, S., Frank, et al
AMER SOC HEMATOLOGY.2022: 4825-4827
 - **Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience**
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C. J., Atrash, S., Khouri, J., Voorhees, P. M., Dima, D., Simmons, G., Kalariya, N., Hovanky, V., Bharadwaj, et al
AMER SOC HEMATOLOGY.2022: 10377-10379
 - **The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease**
Rashid, N., Arora, M., Carpenter, P. A., Alousi, A. M., Hamilton, B. K., Pidala, J., Onstad, L. E., Cutler, C., Flowers, M. E. D., Arai, S., Bhatia, S., Lee, S. J.
AMER SOC HEMATOLOGY.2022: 10519-10520
 - **Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA**
Hosoya, H., Carleton, M., Tanaka, K. L., Sworder, B., Hovanky, V., Duran, G. E., Zhang, T. Y., Khodadoust, M. S., Miklos, D. B., Arai, S., Iberri, D., Liedtke, M., Sidana, et al
AMER SOC HEMATOLOGY.2022: 1546-1548
 - **Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.** *The Lancet. Haematology*
DeZern, A. E., Eapen, M., Wu, J., Talano, J. A., Solh, M., Dávila Saldaña, B. J., Karanes, C., Horwitz, M. E., Mallhi, K., Arai, S., Farhadfar, N., Hexner, E., Westervelt, et al
2022

- **Epidemiology of lower respiratory tract infections and community-acquired respiratory viruses in patients with bronchiolitis obliterans syndrome after hematopoietic cell transplant: a retrospective cohort study.** *Transplantation and cellular therapy*
Epstein, D. J., Liang, E. C., Sharifi, H., Lai, Y. K., Arai, S., Graber-Naidich, A., Sundaram, V., Nelson, J., Hsu, J. L.
2022
- **Durable discontinuation of systemic therapy in patients affected by chronic graft versus host disease.** *Haematologica*
Chen, G. L., Onstad, L., Martin, P. J., Carpenter, P., Pidala, J., Arai, S., Cutler, C., Hamilton, B. K., Lee, S. J., Arora, M.
2022
- **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era.** *Transplantation and cellular therapy*
Liang, E. C., Craig, J., Torelli, S., Cunanan, K., Iglesias, M., Arai, S., Frank, M. J., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R., Rezvani, et al
2022
- **Exploring Potential Innate Immune Targets to Treat Fibrosis and Chronic Inflammation in Chronic Graft-Versus-Host Disease**
Paulson, N., De Souza, C., Cui, L., Lerbs, T., Poyser, J., Kooshesh, M., Saleem, A., Rieger, K., Brown, R., Kwong, B., Fernandez-Po, S., Arai, S., Shizuru, et al
SPRINGER NATURE.2022: 557
- **Real-world Experience of Cryopreserved Allogeneic Hematopoietic Grafts in the COVID-19 Pandemic: A Single Center Report.** *Transplantation and cellular therapy*
Bankova, A. K., Caveney, J., Yao, B., Ramos, T. L., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M. L., Lowsky, R., Brown, J. W., Johnston, L., Rezvani, A. R., Frank, et al
1800
- **Post-Hematopoietic Stem Cell Transplantation Immune-Mediated Anemia: A Literature Review and Novel Therapeutics.** *Blood advances*
Migdady, Y., Pang, Y., Kalsi, S. S., Childs, R. W., Arai, S.
1800
- **CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy**
Frank, M. J., Baird, J. H., Patel, S., Craig, J., Spiegel, J. Y., Ehlinger, Z., Chinnasamy, H., Younes, S. F., Oak, J. S., Natkunam, Y., Reynolds, W. D., Iglesias, M., Crawford, et al
AMER SOC HEMATOLOGY.2021
- **Selective Targeting of Immune Modulatory Proteins to Mitigate Fibrosis and Inflammation in Sclerodermatous Graft-Vs-Host Disease**
Cui, L., De Souza, C., Lerbs, T., Poyser, J., Kooshesh, M., Saleem, A., Rieger, K., Brown, B., Kwong, B., Fernandez-Pol, S., Arai, S., Shizuru, J. A., Mueller, et al
AMER SOC HEMATOLOGY.2021
- **Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant**
Desai, S. H., Spinner, M. A., David, K. A., Bachanova, V., Goyal, G., Azzi, J., Dorritie, K., Kenkre, V. P., Chang, C., Arai, S., Fusco, B., Sumransub, N., Hactic, et al
AMER SOC HEMATOLOGY.2021
- **Mgta-145+Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study**
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamaresis, J., Le, A., Muffly, L., Johnston, L. J., Arai, S., Lowsky, R., Meyer, E. H., Rezvani, A. R., Weng, et al
AMER SOC HEMATOLOGY.2021
- **Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy** *BLOOD ADVANCES*
Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, et al
2021; 5 (21): 4465-4475
- **Initial therapy of chronic graft vs. host disease: Analysis of practice variation and failure-free survival.** *Blood advances*
Pidala, J., Onstad, L., Martin, P. J., Hamilton, B. K., Cutler, C. S., Kitko, C. L., Carpenter, P. A., Chen, G. L., Arora, M., Flowers, M. E., Arai, S., Alousi, A., White, et al

2021

- **Non-relapse mortality among patients diagnosed with chronic GVHD: An updated analysis from The Chronic GVHD Consortium.** *Blood advances*
DeFilipp, Z., Alousi, A., Pidala, J., Carpenter, P. A., Onstad, L., Arai, S., Arora, M., Cutler, C. S., Flowers, M. E., Kitko, C. L., Chen, G. L., Lee, S. J., Hamilton, et al
2021
- **Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.** *Blood advances*
Muffy, L., Sundaram, V., Chen, C., Yurkiewicz, I., Kuo, E., Burnash, S., Spiegel, J. Y., Arai, S., Frank, M. J., Johnston, L. J., Lowsky, R., Meyer, E. H., Negrin, et al
2021; 5 (16): 3147-3151
- **CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.** *Nature medicine*
Spiegel, J. Y., Patel, S., Muffy, L., Hossain, N. M., Oak, J., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J., Iglesias, M., Younes, S., Natkunam, et al
2021
- **Belumosudil for Chronic Graft-versus-Host Disease (cGVHD) After 2 or More Prior Lines of Therapy: The ROCKstar Study.** *Blood*
Cutler, C. S., Lee, S. J., Arai, S., Rotta, M., Zoghi, B., Lazaryan, A., Ramakrishnan, A., DeFilipp, Z., Salhotra, A., Chai-Ho, W., Mehta, R. S., Wang, T., Arora, et al
2021
- **A fructo-oligosaccharide prebiotic is well-tolerated in adults undergoing allogeneic hematopoietic stem cell transplantation: a phase I dose-escalation trial.** *Transplantation and cellular therapy*
Andermann, T. M., Fouladi, F., Tamburini, F. B., Sahaf, B., Tkachenko, E., Greene, C., Buckley, M. T., Brooks, E. F., Hedlin, H., Arai, S., Mackall, C. L., Miklos, D., Negrin, et al
2021
- **Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.** *Bone marrow transplantation*
Lemieux, C., Muffy, L. S., Iberri, D. J., Craig, J. K., Johnston, L. J., Lowsky, R., Shiraz, P., Rezvani, A. R., Frank, M. J., Weng, W., Meyer, E., Shizuru, J. A., Arai, et al
2021
- **Inferior Clinical Outcomes in Recipients of Cryopreserved Grafts Following Reduced Intensity Allogeneic Hematopoietic Cell Transplantation: A Single Center Report**
Bankova, A., Caveney, J., Ramos, T., Bogeholz, J., Heydari, K., Diaz, N., Jackson, M., Lowsky, R., Brown, J., Johnston, L., Rezvani, A., Frank, M., Muffy, et al
SPRINGERNATURE.2021: 181
- **Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.**
Sidana, S., Bankova, A., Hosoya, H., Muffy, L. S., Kumar, S., Johnston, L. J., Lowsky, R., Meyer, E., Rezvani, A., Weng, W., Arai, S., Frank, M., Shiraz, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor vs. G-CSF +/- Plerixafor in the Lenalidomide Era.** *Transplantation and cellular therapy*
Johnsrud, A., Ladha, A., Muffy, L., Shiraz, P., Goldstein, G., Osgood, V., Shizuru, J. A., Johnston, L., Arai, S., Weng, W., Lowsky, R., Rezvani, A. R., Meyer, et al
2021
- **Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.** *Transplantation and cellular therapy*
Liang, E. C., Muffy, L. S., Shiraz, P., Shizuru, J. A., Johnston, L., Arai, S., Frank, M. J., Weng, W., Lowsky, R., Rezvani, A., Meyer, E. H., Negrin, R., Miklos, et al
2021
- **Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma** *BLOOD ADVANCES*

- Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., Meyer, E., Arai, S., Brown, et al
2021; 5 (1): 143–55
- **Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.** *Leukemia*
Merryman, R. W., Castagna, L. n., Giordano, L. n., Ho, V. T., Corradini, P. n., Guidetti, A. n., Casadei, B. n., Bond, D. A., Jaglowski, S. n., Spinner, M. A., Arai, S. n., Lowsky, R. n., Shah, et al
2021
 - **Jun Activation in Dermal Fibroblasts Promotes Fibrosis and Inflammation in Sclerodermatous Graft-vs-host Disease in Mice and Humans**
Mueller, A., Cui, L., Lerbs, T., King, M., Muscat, C., Shibata, T., Lee, J., Brown, R., Fernandez-Pol, S., Arai, S., Shizuru, J., Wernig, G.
SPRINGER NATURE.2020: 13–14
 - **Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.** *Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation*
Lemieux, C., Johnston, L. J., Lowsky, R., Muffly, L. S., Craig, J. K., Shiraz, P., Rezvani, A., Frank, M. J., Weng, W., Meyer, E., Shizuru, J., Arai, S., Negrin, et al
2020
 - **Autologous stem cell transplantation versus no transplant in patients above 70 with multiple myeloma.**
Lemieux, C., Muffly, L. S., Iberri, D., Rezvani, A., Lowsky, R., Frank, M., Craig, J. K., Liedtke, M., Negrin, R., Weng, W., Meyer, E., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
 - **Impact of proteasome inhibitor vs. IMiD maintenance therapy on outcomes of patients with high-risk multiple myeloma (HRMM).**
Tam, E., Iberri, D., Liedtke, M., Muffly, L. S., Shiraz, P., Frank, M., Lowsky, R., Rezvani, A., Negrin, R., Meyer, E., Arai, S., Johnston, L. J., Shizuru, et al
LIPPINCOTT WILLIAMS & WILKINS.2020
 - **Successful treatment of thrombocytopenia with daratumumab after allogeneic transplant: a case report and literature review.** *Blood advances*
Migdady, Y., Ediriwickrema, A., Jackson, R. P., Kadi, W., Gupta, R., Socola, F., Arai, S., Martin, B. A.
2020; 4 (5): 815–18
 - **Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia: Significant Increase in Survival in the Post-Targeted Immunotherapy Era**
Muffly, L., Arai, S., Johnston, L., Lowsky, R., Meyer, E. H., Miklos, D. B., Negrin, R. S., Rezvani, A., Shiraz, P., Shizuru, J. A., Sidana, S., Weng, W., Cunanan, et al
ELSEVIER SCIENCE INC.2020: S106
 - **Organ responses with daratumumab therapy in previously treated AL amyloidosis.** *Blood advances*
Chung, A. n., Kaufman, G. P., Sidana, S. n., Eckhart, E. n., Schrier, S. L., Lafayette, R. A., Arai, S. n., Witteles, R. M., Liedtke, M. n.
2020; 4 (3): 458–66
 - **Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.** *JACC. Heart failure*
Barrett, C. D., Alexander, K. M., Zhao, H. n., Haddad, F. n., Cheng, P. n., Liao, R. n., Wheeler, M. T., Liedtke, M. n., Schrier, S. n., Arai, S. n., Weisshaar, D. n., Witteles, R. M.
2020
 - **CD22-Directed CAR T-Cell Therapy Induces Complete Remissions in CD19-Directed CAR-Refractory Large B-Cell Lymphoma.** *Blood*
Baird, J. H., Frank, M. J., Craig, J. n., Patel, S. n., Spiegel, J. Y., Sahaf, B. n., Oak, J. S., Younes, S. n., Ozawa, M. n., Yang, E. n., Natkunam, Y. n., Tamaresis, J. S., Ehlinger, et al
2020
 - **Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma.** *Blood advances*
Weng, W. K., Arai, S. n., Rezvani, A. n., Johnston, L. n., Lowsky, R. n., Miklos, D. n., Shizuru, J. n., Muffly, L. n., Meyer, E. n., Negrin, R. S., Wang, E. n., Almazan, T. n., Million, et al
2020; 4 (18): 4474–82
 - **Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma.** *Bone marrow transplantation*

- Lemieux, C. n., Muffly, L. S., Rezvani, A. n., Lowsky, R. n., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L. J., Liedtke, M. n., Negrin, R. n., Weng, W. K., Meyer, E. n., Shizuru, et al
2020
- **Grading cardiac response in AL amyloidosis: implications for relapse and survival** *BRITISH JOURNAL OF HAEMATOLOGY*
Eckhart, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
2019; 186 (1): 144–46
 - **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients** *JCI INSIGHT*
Meyer, E. H., Laport, G., Xie, B. J., MacDonald, K., Heydari, K., Sahaf, B., Tang, S., Baker, J., Armstrong, R., Tate, K., Tadisco, C., Arai, S., Johnston, et al
2019; 4 (10)
 - **Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).** *The Lancet. Haematology*
Bolanos-Meade, J., Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Chen, Y., Damon, L. E., Efebera, et al
2019; 6 (3): e132–e143
 - **A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.** *JACC. Heart failure*
Barrett, C. D., Dobos, K. n., Liedtke, M. n., Tuzovic, M. n., Haddad, F. n., Kobayashi, Y. n., Lafayette, R. n., Fowler, M. B., Arai, S. n., Schrier, S. n., Witteles, R. M.
2019
 - **Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort.** *Blood advances*
Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffly, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, J. A., Weng, et al
2019; 3 (16): 2454–64
 - **Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.** *JCI insight*
Meyer, E. H., Laport, G. n., Xie, B. J., MacDonald, K. n., Heydari, K. n., Sahaf, B. n., Tang, S. W., Baker, J. n., Armstrong, R. n., Tate, K. n., Tadisco, C. n., Arai, S. n., Johnston, et al
2019; 4 (10)
 - **Grading cardiac response in AL amyloidosis: implications for relapse and survival.** *British journal of haematology*
Eckhart, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
2018
 - **A Case Report of Refractory Immune Thrombocytopenia (ITP) Following Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplantation (HCT) for Myelodysplastic Syndrome (MDS) Successfully Treated with Off-Label Use of Daratumumab**
Migdady, Y., Gupta, R., Ediriwickrema, A., Socola, F., Arai, S., Martin, B. A.
AMER SOC HEMATOLOGY.2018
 - **Elevated Axicabtagene Ciloleuce (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma**
Spiegel, J. Y., Sahaf, B., Hossain, N., Frank, M. J., Claire, G., Abramian, M., Latchford, T., Villa, B., Cancilla, J., Oak, J., Natkunam, Y., Long, S. R., Arai, et al
AMER SOC HEMATOLOGY.2018
 - **Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)**
Gupta, R., Albabtain, A., Arai, S., Kwong, B., Weng, W.
AMER SOC HEMATOLOGY.2018
 - **Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis**
Eckhart, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
AMER SOC HEMATOLOGY.2018
 - **Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort**

- Spinner, M. A., Kennedy, V. E., Tamaresis, J. S., Lavori, P. W., Elder, L. V., Arai, S., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffy, L. S., Negrin, R. S., Rezvani, A. R., Shizuru, et al
AMER SOC HEMATOLOGY.2018
- **Donor-derived MDS/AML in families with germline GATA2 mutation** *BLOOD*
Galera, P., Hsu, A. P., Wang, W., Droll, S., Chen, R., Schwartz, J. R., Klco, J. M., Arai, S., Maese, L., Zerbe, C., Parta, M. J., Young, N. S., Holland, et al
2018; 132 (18): 1994–98
 - **Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802** *BLOOD ADVANCES*
Holtan, S. G., DeFor, T. E., Panoskaltis-Mortari, A., Khera, N., Levine, J. E., Flowers, M. E. D., Lee, S. J., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Cutler, et al
2018; 2 (15): 1882–88
 - **Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Lee, S. J., Flowers, M. E. D., Storer, B., Onstad, L., Kurukulasuriya, C., Jagasia, M., Hamilton, B., Chen, G., Cutler, C., Broady, R., Arora, M., Pidala, J., Alousi, et al
2018; 24 (8): 1727–32
 - **Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome** *BRITISH JOURNAL OF HAEMATOLOGY*
Kernan, N. A., Grupp, S., Smith, A. R., Arai, S., Triplett, B., Antin, J. H., Lehmann, L., Shore, T., Ho, V. T., Bunin, N., Iacobelli, M., Liang, W., Hume, et al
2018; 181 (6): 816–27
 - **Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation** *BLOOD ADVANCES*
Muffy, L., Sheehan, K., Armstrong, R., Jensen, K., Tate, K., Rezvani, A. R., Miklos, D., Arai, S., Shizuru, J., Johnston, L., Meyer, E., Weng, W., Laport, et al
2018; 2 (6): 681–90
 - **Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells**
Meyer, E., Laport, G. G., Tantsura, I., Tang, S., Sahaf, B., Rangarajan, K., Armstrong, R., Tate, K., Tudisco, C., Sheehan, K., Arai, S., Johnston, L., Muffy, et al
ELSEVIER SCIENCE INC.2018: S145
 - **Amphiregulin Modifies the Minnesota Acute Graft-Versus-Host Disease Risk Score: Results from BMT CTN Acute Gvhd Therapy Trials**
Holtan, S. G., DeFor, T. E., Howard, A., Pidala, J. A., Levine, J. E., Wu, J., Khera, N., Lee, S. J., Bolanos-Meade, J., Ho, V. T., Alousi, A. M., Inamoto, Y., Chen, et al
ELSEVIER SCIENCE INC.2018: S177–S178
 - **Donor Derived MDS/AML in Patients with Germline GATA2 Mutations**
Galera, P., Hsu, A., Wang, W., Schwartz, J. R., Klco, J., Arai, S., Holland, S. M., Hickstein, D., Calvo, K.
NATURE PUBLISHING GROUP.2018: 516–17
 - **Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Chen, G. L., Carpenter, P. A., Broady, R., Gregory, T. K., Johnston, L. J., Storer, B. E., Beumer, J. H., Qiu, J., Cerda, K., Le, R., Otani, J. M., Liu, H., Ross, et al
2018; 24 (2): 373–80
 - **Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Hamilton, B. K., Rybicki, L., Arai, S., Arora, M., Cutler, C. S., Flowers, M. E. D., Jagasia, M., Martin, P. J., Palmer, J., Pidala, J., Majhail, N. S., Lee, S. J., Khera, et al
2018; 24 (2): 393–99
 - **Potential Association of Anti-CCR4 Antibody Mogamulizumab and Graft-vs-Host Disease in Patients With Mycosis Fungoides and Sézary Syndrome.** *JAMA dermatology*
Dai, J. n., Almazan, T. H., Hong, E. K., Khodadoust, M. S., Arai, S. n., Weng, W. K., Kim, Y. H.
2018

- **The Cost of Hematopoietic Stem-Cell Transplantation in the United States** *AMERICAN HEALTH AND DRUG BENEFITS*
Broder, M. S., Quock, T. P., Chang, E., Reddy, S. R., Agarwal-Hashmi, R., Arai, S., Villa, K. F.
2017; 10 (7): 366–73
- **Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Veeraputhiran, M., Yang, L., Sundaram, V., Arai, S., Lowsky, R., Miklos, D., Meyer, E., Muffy, L., Negrin, R., Rezvani, A., Shizuru, J., Weng, W., Johnston, et al
2017; 23 (10): 1744–48
- **Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis** *BLOOD*
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., Liedtke, M.
2017; 130 (7): 900–902
- **An endpoint associated with clinical benefit after initial treatment for chronic graft-versus-host disease.** *Blood*
Martin, P. J., Storer, B. E., Inamoto, Y., Flowers, M. E., Carpenter, P. A., Pidala, J., Palmer, J., Arora, M., Jagasia, M., Arai, S., Cutler, C., Lee, S. J.
2017
- **HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity.** *Blood advances*
Spinner, M. A., Fernández-Viña, M. n., Creary, L. E., Quinn, O. n., Elder, L. n., Arai, S. n., Johnston, L. J., Meyer, E. H., Miklos, D. B., Muffy, L. S., Negrin, R. S., Shizuru, J. A., Weng, et al
2017; 1 (17): 1347–57
- **Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors** *BLOOD*
Holtan, S. G., Khera, N., Levine, J. E., Chai, X., Storer, B., Liu, H. D., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Flowers, M. E., Cutler, et al
2016; 128 (19): 2350-2358
- **Clinicopathologic Threshold of Acute Colorectal Graft-versus-Host Disease** *ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE*
Gomez, A. J., Arai, S., Higgins, J. P., Kambham, N.
2016; 140 (6): 570-577
- **Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia.** *Leukemia*
Khodadoust, M. S., Luo, B., Medeiros, B. C., Johnson, R. C., Ewalt, M. D., Schalkwyk, A. S., Bangs, C. D., Cherry, A. M., Arai, S., Arber, D. A., Zehnder, J. L., Gotlib, J.
2016; 30 (4): 947-950
- **Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium.** *Oral diseases*
Yuan, A., Chai, X., Martins, F., Arai, S., Arora, M., Correa, M. E., Pidala, J., Cutler, C. S., Lee, S. J., Treister, N. S.
2016; 22 (3): 235-240
- **Long-awaited news for hepatic veno-occlusive disease.** *Blood*
Arai, S.
2016; 127 (13): 1630-1631
- **Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.** *Blood*
Richardson, P. G., Riches, M. L., Kernan, N. A., Brochstein, J. A., Mineishi, S., Termuhlen, A. M., Arai, S., Grupp, S. A., Guinan, E. C., Martin, P. L., Steinbach, G., Krishnan, A., Nemecek, et al
2016; 127 (13): 1656-1665
- **Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.** *Biology of blood and marrow transplantation*
Arora, M., Cutler, C. S., Jagasia, M. H., Pidala, J., Chai, X., Martin, P. J., Flowers, M. E., Inamoto, Y., Chen, G. L., Wood, W. A., Khera, N., Palmer, J., Duong, et al
2016; 22 (3): 449-455
- **A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.** *Clinical cancer research*
Arai, S., Pidala, J., Pusic, I., Chai, X., Jaglowski, S., Khera, N., Palmer, J., Chen, G. L., Jagasia, M. H., Mayer, S. A., Wood, W. A., Green, M., Hyun, et al

2016; 22 (2): 319-327

- **Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning** *BONE MARROW TRANSPLANTATION*
Rezvani, A. R., Kanate, A. S., Efron, B., Chhabra, S., Kohrt, H. E., Shizuru, J. A., Laport, G. G., Miklos, D. B., Benjamin, J. E., JOHNSTON, L. J., Arai, S., Weng, W., Negrin, et al
2015; 50 (10): 1286-1292
- **Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study** *LANCET HAEMATOLOGY*
Anderlini, P., Wu, J., Gersten, I., Ewell, M., Tolar, J., Antin, J. H., Adams, R., Arai, S., Eames, G., Horwitz, M. E., McCarty, J., Nakamura, R., Pulsipher, et al
2015; 2 (9): E367-E375
- **Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease** *HAEMATOLOGICA*
Palmer, J., Chai, X., Martin, P. J., Weisdorf, D., Inamoto, Y., Pidala, J., Jagasia, M., Pavletic, S., Cutler, C., Vogelsang, G., Arai, S., Flowers, M. E., Lee, et al
2015; 100 (5): 690-695
- **Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.** *American journal of transplantation*
Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., Lafayette, R., Coakley, T., Witteles, R. M.
2015; 15 (3): 650-658
- **National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.** *Biology of blood and marrow transplantation*
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G., Kerr, H., Stratton, P., Duarte, et al
2015; 21 (3): 389-401 e1
- **National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.** *Biology of blood and marrow transplantation*
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G., Kerr, H., Stratton, P., Duarte, et al
2015; 21 (3): 389-401 e1
- **Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research.** *Biology of blood and marrow transplantation*
Arai, S., Arora, M., Wang, T., Spellman, S. R., He, W., Couriel, D. R., Urbano-Ispizua, A., Cutler, C. S., Bacigalupo, A. A., Battiwalla, M., Flowers, M. E., Juckett, M. B., Lee, et al
2015; 21 (2): 266-274
- **Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile.** *Bone marrow transplantation*
Percival, M. M., Medeiros, B. C., Tian, L. n., Robeson, S. n., Laport, G. G., Johnston, L. J., Shizuru, J. A., Miklos, D. B., Arai, S. n., Weng, W. K., Negrin, R. S., Lowsky, R. n.
2015
- **Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease** *HAEMATOLOGICA*
Inamoto, Y., Martin, P. J., Storer, B. E., Palmer, J., Weisdorf, D. J., Pidala, J., Flowers, M. E., Arora, M., Jagasia, M., Arai, S., Chai, X., Pavletic, S. Z., Vogelsang, et al
2014; 99 (10): 1618-1623
- **Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease.** *Haematologica*
Inamoto, Y., Martin, P. J., Storer, B. E., Palmer, J., Weisdorf, D. J., Pidala, J., Flowers, M. E., Arora, M., Jagasia, M., Arai, S., Chai, X., Pavletic, S. Z., Vogelsang, et al
2014; 99 (10): 1618-1623
- **Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms.** *Biology of blood and marrow transplantation*
Benjamin, J., Chhabra, S., Kohrt, H. E., Lavori, P., Laport, G. G., Arai, S., Johnston, L., Miklos, D. B., Shizuru, J. A., Weng, W., Negrin, R. S., Lowsky, R.

2014; 20 (6): 837-843

- **Assessment of Joint and Fascia Manifestations in Chronic Graft-Versus-Host Disease** *ARTHRITIS & RHEUMATOLOGY*
Inamoto, Y., Pidala, J., Chai, X., Kurland, B. F., Weisdorf, D., Flowers, M. E., Palmer, J., Arai, S., Jacobssohn, D., Cutler, C., Jagasia, M., Goldberg, J. D., Martin, et al
2014; 66 (4): 1044-1052
- **Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.** *Biology of blood and marrow transplantation*
Palmer, J., Williams, K., Inamoto, Y., Chai, X., Martin, P. J., Tomas, L. S., Cutler, C., Weisdorf, D., Kurland, B. F., Carpenter, P. A., Pidala, J., Pavletic, S. Z., Wood, et al
2014; 20 (3): 337-344
- **Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis** *HEART RHYTHM*
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., Schrier, S. L., Witteles, R. M.
2014; 11 (1): 158-162
- **Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma.** *Science translational medicine*
Weng, W., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., Kim, Y. H.
2013; 5 (214): 214ra171-?
- **Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma** *SCIENCE TRANSLATIONAL MEDICINE*
Weng, W., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., Kim, Y. H.
2013; 5 (214)
- **Comorbidity burden in patients with chronic GVHD** *BONE MARROW TRANSPLANTATION*
Wood, W. A., Chai, X., Weisdorf, D., Martin, P. J., Cutler, C., INAMOTO, Y., WOLFF, D., Pavletic, S. Z., Pidala, J., Palmer, J. M., Arora, M., Arai, S., Jagasia, et al
2013; 48 (11): 1429-1436
- **Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.** *Haematologica*
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., Schrier, S. L., Liedtke, M.
2013; 98 (10): 1593-1599
- **Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium** *BONE MARROW TRANSPLANTATION*
Treister, N., Chai, X., Kurland, B., Pavletic, S., Weisdorf, D., Pidala, J., Palmer, J., Martin, P., INAMOTO, Y., Arora, M., Flowers, M., Jacobssohn, D., Jagasia, et al
2013; 48 (8): 1123-1128
- **The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis** *BRITISH JOURNAL OF HAEMATOLOGY*
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., George, T. I., Schrier, S. L., Liedtke, M.
2013; 161 (3): 367-372
- **H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Sahaf, B., Yang, Y., Arai, S., Herzenberg, L. A., Herzenberg, L. A., Miklos, D. B.
2013; 110 (8): 3005-3010
- **Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.** *Leukemia & lymphoma*
Arai, S. n., Fanale, M. n., DeVos, S. n., Engert, A. n., Illidge, T. n., Borchmann, P. n., Younes, A. n., Morschhauser, F. n., McMillan, A. n., Horning, S. J.
2013; 54 (11): 2531-33
- **Successful Surgical and Medical Treatment of Rhizopus Osteomyelitis Following Hematopoietic Cell Transplantation** *ORTHOPEDICS*
Vashi, N., Avedian, R., Brown, J., Arai, S.
2012; 35 (10): E1556-E1561

- **Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium** *BLOOD*
Jacobsohn, D. A., Kurland, B. F., Pidala, J., Inamoto, Y., Chai, X., Palmer, J. M., Arai, S., Arora, M., Jagasia, M., Cutler, C., Weisdorf, D., Martin, P. J., Pavletic, et al
2012; 120 (13): 2545-2552
- **Fludarabine-Based Conditioning for Marrow Transplantation from Unrelated Donors in Severe Aplastic Anemia: Early Results of a Cyclophosphamide Dose Deescalation Study Show Life-Threatening Adverse Events at Predefined Cyclophosphamide Dose Levels** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Tolar, J., Deeg, H. J., Arai, S., Horwitz, M., Antin, J. H., McCarty, J. M., Adams, R. H., Ewell, M., Leifer, E. S., Gersten, I. D., Carter, S. L., Horowitz, M. M., Nakamura, et al
2012; 18 (7): 1007-1011
- **Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence** *BLOOD*
Arai, S., Sahaf, B., Narasimhan, B., Chen, G. L., Jones, C. D., Lowsky, R., Shizuru, J. A., Johnston, L. J., Laport, G. G., Weng, W., Benjamin, J. E., Schaeffer, J., Brown, et al
2012; 119 (25): 6145-6154
- **More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis** *ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY*
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., Afghahi, A., Liedtke, M.
2012; 138 (5): 509-511
- **Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
Johnston, L., Florek, M., Armstrong, R., McCune, J. S., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Sheehan, K., Lavori, P., Negrin, et al
2012; 47 (4): 581-588
- **Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma** *BONE MARROW TRANSPLANTATION*
Chen, A. I., Negrin, R. S., McMillan, A., Shizuru, J. A., JOHNSTON, L. J., Lowsky, R., Miklos, D. B., Arai, S., Weng, W., Laport, G. G., Stockerl-Goldstein, K.
2012; 47 (4): 516-521
- **Overlap subtype of chronic graft-versus-host disease is associated with an adverse prognosis, functional impairment, and inferior patient-reported outcomes: a Chronic Graft-versus-Host Disease Consortium study** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Pidala, J., Vogelsang, G., Martin, P., Chai, X., Storer, B., Pavletic, S., Weisdorf, D. J., Jagasia, M., Cutler, C., Palmer, J., Jacobsohn, D., Arai, S., Lee, et al
2012; 97 (3): 451-458
- **Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies** *JOURNAL OF HEART AND LUNG TRANSPLANTATION*
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.
2012; 31 (3): 325-331
- **Adoptive Immunotherapy with Cytokine-Induced Killer Cells for Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Laport, G. G., Sheehan, K., Baker, J., Armstrong, R., Wong, R. M., Lowsky, R., Johnston, L. J., Shizuru, J. A., Miklos, D., Arai, S., Benjamin, J. E., Weng, W., Negrin, et al
2011; 17 (11): 1679-1687
- **A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRα antibodies** *BLOOD*
Chen, G. L., Arai, S., Flowers, M. E., Otani, J. M., Qiu, J., Cheng, E. C., McMillan, A., Johnston, L. J., Shizuru, J. A., Miklos, D. B.
2011; 118 (15): 4070-4078
- **Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria** *BLOOD*
Arai, S., Jagasia, M., Storer, B., Chai, X., Pidala, J., Cutler, C., Arora, M., Weisdorf, D. J., Flowers, M. E., Martin, P. J., Palmer, J., Jacobsohn, D., Pavletic, et al
2011; 118 (15): 4242-4249

- **Rationale and Design of the Chronic GVHD Cohort Study: Improving Outcomes Assessment in Chronic GVHD** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Lee, S. J., Flowers, M. E., Martin, P. J., Carpenter, P., Hansen, J., Chai, X., Kurland, B., Storer, B., Arai, S., Johnston, L., Miklos, D., Weisdorf, D., Arora, et al
2011; 17 (8): 1114-1120
- **Short tandem repeat and human leukocyte antigen mutations or losses confound engraftment and typing analysis in hematopoietic stem cell transplants** *HUMAN IMMUNOLOGY*
Pereira, S., Vayntrub, T., Hiraki, D. D., Cherry, A. M., Arai, S., Dvorak, C. C., Grumet, F. C.
2011; 72 (6): 503-509
- **Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative Hematopoietic Cell Transplantation with a Total Lymphoid Irradiation and Antithymocyte Globulin Preparative Regimen** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Schaenman, J. M., Shashidhar, S., Rhee, C., Wong, J., Navato, S., Wong, R. M., Ho, D. Y., Arai, S., Johnston, L., Brown, J. M.
2011; 17 (5): 693-702
- **Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium** *BLOOD*
Pidala, J., Kurland, B., Chai, X., Majhail, N., Weisdorf, D. J., Pavletic, S., Cutler, C., Jacobsohn, D., Palmer, J., Arai, S., Jagasia, M., Lee, S. J.
2011; 117 (17): 4651-4657
- **Long-term outcomes in patients with high-risk myeloid malignancies following matched related donor hematopoietic cell transplantation with myeloablative conditioning of BU, etoposide and CY** *BONE MARROW TRANSPLANTATION*
Naik, S., Wong, R., Arai, S., Brown, J., Laport, G., Lowsky, R., Miklos, D., Shizuru, J., Blume, K., Negrin, R., Johnston, L.
2011; 46 (2): 192-199
- **Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia** *BRITISH JOURNAL OF HAEMATOLOGY*
Jones, C. D., Arai, S., Lowsky, R., Tyan, D. B., Zehnder, J. L., Miklos, D. B.
2010; 150 (5): 637-639
- **Phase I/II Trial of GN-BVC, a Gemcitabine and Vinorelbine-Containing Conditioning Regimen for Autologous Hematopoietic Cell Transplantation in Recurrent and Refractory Hodgkin Lymphoma** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*
Arai, S., Letsinger, R., Wong, R. M., Johnston, L. J., Laport, G. G., Lowsky, R., Miklos, D. B., Shizuru, J. A., Weng, W., Lavori, P. W., Blume, K. G., Negrin, R. S., Horning, et al
2010; 16 (8): 1145-1154
- **Rituximab in hematopoietic cell transplantation** *EXPERT OPINION ON BIOLOGICAL THERAPY*
Arai, S., Miklos, D. B.
2010; 10 (6): 971-982
- **TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors** *BLOOD*
Kohrt, H. E., Turnbull, B. B., Heydari, K., Shizuru, J. A., Laport, G. G., Miklos, D. B., Johnston, L. J., Arai, S., Weng, W., Hoppe, R. T., Lavori, P. W., Blume, K. G., Negrin, et al
2009; 114 (5): 1099-1109
- **High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation** *BONE MARROW TRANSPLANTATION*
Majhail, N. S., Flowers, M. E., Ness, K. K., Jagasia, M., Carpenter, P. A., Arora, M., Arai, S., Johnston, L., Martin, P. J., Baker, K. S., Lee, S. J., Burns, L. J.
2009; 43 (1): 49-54
- **Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial** *CYTOTHERAPY*
Arai, S., Meagher, R., Swearingen, M., Myint, H., Rich, E., Martinson, J., Klingemann, H.
2008; 10 (6): 625-632
- **A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Kurian, A. W., Newton Thompson, R., Gaw, A. F., Arai, S., Ortiz, R., Garber, A. M.
2007; 25 (6): 634-641

- **Natural killer cells: can they be useful as adoptive immunotherapy for cancer?** *Expert Opin Biol Ther*
Arai S, Klingemann H-G
2005; 5: 163-172
- **Regulation of OX40 gene expression in graft-versus- host disease** *20th International Congress of the Transplantation-Society*
Miura, Y., Thoburn, C. J., Bright, E. C., Arai, S., Hess, A. D.
ELSEVIER SCIENCE INC.2005: 57-61
- **Association of Foxp3 regulatory gene expression and graft-versus-host disease** *Blood*
Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD
2004; 104: 2187-93
- **Role of immunotherapy in stem cell transplantation** *INTERNATIONAL JOURNAL OF HEMATOLOGY*
Arai, S., Klingemann, H. G.
2003; 77 (1): 22-28
- **Poor outcome in steroid refractory GVHD with ATG treatment** *Biol Blood Marrow Transplant*
Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB
2002; 8: 155-60
- **Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings** *BONE MARROW TRANSPLANTATION*
Vogelsang, G. B., Arai, S.
2001; 27 (12): 1255-1262
- **von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy** *The Hematology Journal*
Arai S, Allan C, Streiff M, Hutchins GM, Vogelsang GB, Tsai HM
2001; 2: 292-299
- **Management of graft-versus-host disease** *BLOOD REVIEWS*
Arai, S., Vogelsang, G. B.
2000; 14 (4): 190-204